ZNF565 Inhibitors
Chemical inhibitors of ZNF565 can interact with various signaling pathways and enzymes to modulate its activity. PD168393, an irreversible inhibitor of the EGFR tyrosine kinase, binds to the ATP binding site of the enzyme, resulting in the disruption of downstream signaling pathways that are crucial for the functional regulation of ZNF565. Similarly, Gefitinib selectively inhibits EGFR tyrosine kinase, impacting the cell signaling pathways that interact with ZNF565. SU5402, a selective inhibitor of the FGFR tyrosine kinase, blocks the FGFR signaling pathway that can modulate proteins which, either directly or indirectly, regulate the activity of ZNF565. Furthermore, the specific inhibition of PI3K by LY294002 and Wortmannin prevents the phosphorylation of downstream targets, which may include signaling pathways regulating ZNF565, leading to a decrease in its functional activity.
Additionally, SB203580 targets p38 MAP kinase, which is involved in cellular responses to various stimuli, and by inhibiting this kinase, it can disrupt the signaling required for the optimal activity of ZNF565. The inhibition of mTOR by Rapamycin also affects ZNF565 by altering the cellular environment and signaling pathways upon which it may rely. U0126, as an inhibitor of MEK1/2, leads to decreased activation of ERK, another kinase that could be essential for the regulation of ZNF565 function. PP2, which inhibits Src family tyrosine kinases, and Dasatinib, a broad-spectrum tyrosine kinase inhibitor, both reduce the phosphorylation of substrates in signaling pathways that regulate the activity of ZNF565. Inhibition of Rho-associated protein kinase (ROCK) by Y-27632 could alter actin cytoskeleton and cell motility, which may be necessary for ZNF565's function. Lastly, SP600125, an inhibitor of the c-Jun N-terminal kinase (JNK), influences stress response pathways that are implicated in the regulation of ZNF565, thus contributing to the inhibition of its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 168393 | 194423-15-9 | sc-222138 | 1 mg | $162.00 | 4 | |
PD168393 is an irreversible inhibitor of EGFR tyrosine kinase, which interacts with the ATP binding site of the enzyme. By inhibiting EGFR, downstream signaling pathways that may be crucial for the functional regulation of ZNF565 are impacted, leading to its inhibition. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $62.00 $96.00 | 36 | |
SU5402 is a potent and selective inhibitor of the FGFR tyrosine kinase. It blocks the FGFR signaling pathway that could be responsible for activating proteins that directly or indirectly modulate ZNF565's activity, hence its inhibition by SU5402 leads to a reduction in ZNF565 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. It prevents PI3K from phosphorylating downstream targets crucial for various signaling pathways, including those that may regulate ZNF565, resulting in its functional inhibition. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase, which is involved in cellular responses to stress and inflammation. Inhibition of p38 MAPK can disrupt the signaling required for the optimal activity of ZNF565, leading to its inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR, a key regulator of cell growth and metabolism. The inhibition of mTOR can negatively affect the cellular environment and signaling pathways that ZNF565 may rely on for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are kinases in the MAPK/ERK pathway. Inhibition of MEK1/2 leads to decreased activation of ERK, which could be essential for the regulation of ZNF565 function, thereby inhibiting its activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an Src family tyrosine kinase inhibitor. Inhibiting Src family kinases with PP2 can reduce the phosphorylation of substrates involved in signaling pathways that may regulate the activity of ZNF565, leading to its inhibition. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK). Inhibition of ROCK can alter the actin cytoskeleton and cell motility, which may be necessary for the functional regulation of ZNF565, thus inhibiting its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK), which plays a role in stress responses. By inhibiting JNK, SP600125 can affect the signaling pathways that regulate the function of ZNF565, leading to its inhibition. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K. Similar to LY294002, it affects the PI3K pathway and downstream signaling, which can play a role in the regulation of ZNF565, leading to its functional inhibition. | ||||||